The Dipeptidyl Peptidase 4 Inhibitor Vildagliptin Does Not Accentuate Glibenclamide-Induced Hypoglycemia but Reduces Glucose-Induced Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide Secretion
Year: 2007
Type: article
Study design: Clinical Trial
DOI: 10.1210/jc.2006-1932
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Keywords: vildagliptin, glibenclamide, sulfonylurea-induced hypoglycemia, DPP-4 inhibition, glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, incretin secretion, oral glucose tolerance test, negative feedback regulation, incretin-based therapy, drug interactions, type 2 diabetes treatment, glycemic control
Open Access status: closed
Funder: Novartis Pharma
OpenAlex ID: W2117891623
